

# Red light-triggered anti-angiogenic and photodynamic combination therapy of age-related macular degeneration




Shuting Xu<sup>1, 2, 3</sup>, Kaixuan Cui<sup>4</sup>, Kaiqi Long<sup>1, 2, 3</sup>, Jia Li<sup>1, 2, 3</sup>, Ni Fan<sup>1, 2, 3</sup>, Wai-Ching Lam<sup>5</sup>, Xiaoling Liang<sup>4</sup>, Weiping Wang<sup>1, 2, 3</sup>

<sup>1</sup> State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China  
<sup>2</sup> Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.  
<sup>3</sup> Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Hong Kong, China.  
<sup>4</sup> State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.  
<sup>5</sup> Department of Ophthalmology, Vancouver General Hospital, Vancouver, Canada


## BACKGROUND

Exudative age-related macular degeneration (wAMD) is a leading cause of irreversible vision loss in the elderly, which is characterized by choroidal neovascularization (CNV).

The limitations of the current standard therapy with anti-vascular endothelial growth factor (VEGF) agents included the safety concerns of invasive intravitreal administration and insufficient efficacy for neovascular occlusion.




## ABSTRACT SUMMARY



In this study, we report a novel and minimally invasive approach to achieve anti-angiogenic and photodynamic combination therapy of wAMD by intravenous administration of photoactivatable nanoparticles (Di-DAS-VER NPs).

## NANOPARTICLE CHARACTERIZATION




**Fig.1** Characterization of Di-DAS-VER NPs. (a). Hydrodynamic size distribution and transmission electron microscope image of Di-DAS-VER NPs. (b). UV-Vis absorption spectra of free Di-DAS, verteporfin (VER) and Di-DAS-VER NPs. (c). Representative HPLC chromatograms of Di-DAS-VER NPs upon 690 nm laser irradiation (100 mW/cm<sup>2</sup>) and quantitative analysis of Di-DAS degradation rates.

**ACKNOWLEDGMENTS:** This work was supported by the National Natural Science Foundation of China Excellent Young Scientists Fund (82222903) and the National Natural Science Foundation of China (82271099).


**CONTACT INFORMATION:** Shuting Xu: xust0227@connect.hku.hk; Dr. Weiping Wang: wangwp@hku.hk

## IN VITRO THERAPEUTIC EVALUATION



**Fig.2** In vitro photoactivatable anti-angiogenesis evaluation. (a). Representative images and the quantification results of VEGF-stimulated human umbilical vein endothelial cell (HUVEC) tube formation assay of Di-DAS-VER NPs at 4 h post-treatment. (b). Representative images and the quantification results of Western blot analysis of pro-angiogenic signaling proteins. (c). Quantitative HUVEC cell viability of Di-DAS-VER NPs by MTT assay.

## IN VIVO CNV SUPPRESSION



**Fig.2** In vivo CNV suppression in a laser-induced CNV mouse model. (a). Schematic illustration of the treatment process with Di-DAS-VER NPs in CNV mice. (b). LC-MS/MS quantitative analysis of ocular DAS concentration of CNV mice at 2 h post-intravenous injection of Di-DAS-VER NPs with or without 690 nm light irradiation. (c-d). Representative fundus fluorescein angiography images and the quantification results of CNV regions on days 8 and 13. (e). Clinical grading of the fluorescein leakage degree on day 13. (f-g). Representative confocal images of anti-CD31 immunofluorescence-stained vessels of RPE-choroid flat-mounts and the corresponding quantification results of the CNV areas.

## CONCLUSION

- ✓ Red light-triggered intraocular drug release strategy was applied to achieve anti-angiogenic and PDT combination treatment of wAMD via intravenous administration.
- ✓ We have confirmed photoactivatable anti-angiogenic ability and efficient intraocular DAS release from Di-DAS-VER NPs upon light irradiation.
- ✓ Di-DAS-VER NPs strengthened CNV suppression effect compared with anti-angiogenic or PDT monotherapy *in vivo*.